Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: A prospective phase I subanalysis

Nintedanib is a potent, oral angiokinase inhibitor that targets VEGF, PDGF and FGF signalling, as well as RET and Flt3. The maximum tolerated dose of nintedanib was evaluated in a phase I study of treatment-refractory patients with advanced solid tumours.